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Abstract
Background: Identification of gene variants plays an important role in research on and diagnosis of genetic diseases. A
combination of enrichment of targeted genes and next-generation sequencing (targeted DNA-HiSeq) results in both high
efficiency and low cost for targeted sequencing of genes of interest.
Methodology/Principal Findings: To identify mutations associated with genetic diseases, we designed an array-based gene
chip to capture all of the exons of 193 genes involved in 103 genetic diseases. To evaluate this technology, we selected 7
samples from seven patients with six different genetic diseases resulting from six disease-causing genes and 100 samples
from normal human adults as controls. The data obtained showed that on average, 99.14% of 3,382 exons with more than
30-fold coverage were successfully detected using Targeted DNA-HiSeq technology, and we found six known variants in
four disease-causing genes and two novel mutations in two other disease-causing genes (the STS gene for XLI and the FBN1
gene for MFS) as well as one exon deletion mutation in the DMD gene. These results were confirmed in their entirety using
either the Sanger sequencing method or real-time PCR.
Conclusions/Significance: Targeted DNA-HiSeq combines next-generation sequencing with the capture of sequences from
a relevant subset of high-interest genes. This method was tested by capturing sequences from a DNA library through
hybridization to oligonucleotide probes specific for genetic disorder-related genes and was found to show high selectivity,
improve the detection of mutations, enabling the discovery of novel variants, and provide additional indel data. Thus,
targeted DNA-HiSeq can be used to analyze the gene variant profiles of monogenic diseases with high sensitivity, fidelity,
throughput and speed.
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Introduction
Genetic disorders are diseases caused by abnormalities in an
individual’s genome, including single-nucleotide variants (SNVs),
small inversion and deletion (indel) and gross chromosomal
abnormalities. Genetic disorders can be divided into single-gene
disorders and multifactorial and polygenic disorders. Since the
human genome project was completed in 2003, many other
projects have been launched to identify genomic variants [1],
including the 1000 Human Genomes Project (http://www.
1000genomes.org/), the International HapMap Project [2], and
the Cancer Genome Anatomy Project (http://cgap.nci.nih.gov/).
To date, more than 100,000 mutations have been stored in the
Human Gene Mutation Database (HGMD) at the Institute of
Medical Genetics in Cardiff; 55.8% of these mutations are
missense or nonsense mutations, and the others are indel and
splicing mutations. More than 8,000 mutations have been added
to the HGMD per year for the last 6 years. According to statistics
reported by the OMIM database, there are over 6,000 single-gene
disorders related to 12,000 genes with different variants. Extensive
re-sequencing is required to explore the sequences of many
disease-associated genes at the sequence and structural level.
The Sanger DNA sequencing method, which is well known for
both the read length and accuracy of sequencing it provides, has
been considered to represent the gold standard for screening
variantsofgenesofinterestinmanyscientificfieldsforbothresearch
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for mutations simultaneously, the gathering of information becomes
laborious, expensive and time consuming using the Sanger method.
Hence, this technique is not suitable for the identification of a large
number of sequence variants in massive samples in one experiment.
Since 2005, several next-generation sequencing (NGS) platforms
have been established, including the Illumina HiSeq2000, the
Roche 454, and the ABI SOLiD platforms, all of which are able to
generate a massive amount of sequence data [3]. Although NGS
technology can be used to analyze gene variants with high
throughput screening, its high cost still prevents its application in
whole human genome resequencing projects. Therefore, targeted
sequence analysis of interesting genomic regions is an attractive
approach that can be used to develop novel applications. The
combination of targeted enrichment systems with NGS has been
used in research on both complex diseases and single-gene disorders
[4–6]. Several sophisticated target-capture methods have been
developed to either capture the entire human exome or provide
customized capture of regions of interest [7–10], including the
Agilent SureSelect target-enrichment system and the Nimblegen
solid-phase hybrid array.
NGS platforms, coupled with DNA target-capture using solid-
phase arrays and multiple sample barcoding technology, have
become a powerful tool for identifying genetic variants. Recent
explorations into hundreds of candidate disease genes in different
individuals have demonstrated the possibility of low-cost genetic
screening [11,12]. In this study, we have designed a custom high-
density, solid-phase array (Roche NimbleGen, Inc., Madison, WI,
USA) to capture 193 distinct genes involved in 103 different
genetic diseases. After enrichment, high-throughput sequencing
using the Illumina HiSeq2000 Analyzer (Illumina, San Diego, CA,
USA) was performed to analyze the variants of disease-causing
genes in different patient samples in one sequencing lane using the
sample barcoding method. Next, we used the Sanger DNA
sequencing method followed by PCR amplification and MOLDI-
TOF-MS to confirm the results obtained from NGS. Our current
findings suggest that this targeted DNA-HiSeq technology can be
used to detect variants of disease-causing genes with high fidelity,
high throughput, high speed and low cost.
Methods
Patients and controls
A total of 107 blood samples were used in this study from 7
clinical cases: one with hereditary spastic paraplegia with thin
corpus callosum (HSP-TCC, MIM# 604360), one with X-linked
ichthyosis (XLI, MIM# 308100), one with Marfan syndrome
(MFS, MIM# 154700), one with Wilson disease (MIM# 277900),
one with Duchenne muscular dystrophy (DMD, MIM# 310200)
and two patients with b-thalassemias (MIM# 603902) (Table 1),
and 100 normal human adults as controls. In addition, 3 samples
derived from YH DNA (C1), one additional normal human adult
(C2) and the mother (C3) of the DMD proband (P7) were analyzed
(Table 1). Written informed consent was obtained from all of the
participants, who each provided 5 ml of blood for the study. This
project and the protocols for the investigation involving human
tissues were approved by the ethics committee of the Beijing
Genomics Institute at Shenzhen.
Capture array design, library construction and
next-generation sequencing
A custom capture array (NimbleGen, Roche) was designed to
capture all exons (3382), splice sites and the immediately adjacent
intron sequences of 193 genes known to be associated with three
main types of hereditary diseases according to GeneReviews
(NCBI), including single-gene disorders, malignant arrhythmias
and cardiomyopathies, as well as familial malignant neoplasms.
The methods used for DNA target capture, enrichment and
elution followed previously described protocols with minor
modifications (Roche NimbleGen, Inc.). Briefly, genomic DNA
from peripheral blood was extracted from the 110 samples using
the QIAamp DNA BloodMiNi Kit (Qiagen, Hilden, Germany),
and fragmentation of the DNA into fragments ranging from
200 bp to 300 bp was performed using an ultrasonoscope (Covaris
S2, Massachusetts, USA). Next, 1 mg of purified DNA (quantified
by NanoDrop) was treated with T4 DNA polymerase, T4
phosphonucleotide kinase and the Klenow fragment of Escherichia
coli DNA polymerase to fill 59 overhangs and remove 39 overhangs.
Terminal A residues were added following a brief incubation with
dATP and the Klenow 39-59 exo-enzyme following standard
Illumina protocols [13]. Adapter oligonucleotides from Illumina
(single reads) were ligated to the ends. After the ligation was
completed, successful adapter ligation was confirmed by 4-cycle
PCR using a high-fidelity polymerase with PCR primers
containing a custom-synthesized barcode sequence (8 bp) as a
sample index signature. PCR was used to generate a library for
further analysis, and the DNA adapter-ligated and indexed
fragments from 10 libraries were pooled and hybridized to the
capture array for 72 h. After hybridization and washing, the DNA
Table 1. Overview of performance of Targeted DNA-HiSeq.
Sample Gender Total reads mapped reads Capture efficiency Coverage of target region Mean coverage
C1 Male 10 481 008 7 496 661 71.53% 99.57% 393.97
C2 Female 15 185 260 11 080 462 72.97% 99.69% 570.11
C3 Female 14 058 272 10 040 422 71.42% 99.58% 515.10
P1 Male 12 485 604 8 843 811 70.83% 99.35% 455.99
P2 Male 11 134 408 7 916 144 71.10% 99.52% 407.10
P3 Female 6 932 866 5 124 501 73.92% 99.55% 264.84
P4 Female 11 173 742 7 895 879 70.66% 99.62% 404.24
P5 Male 5 981 308 4 403 481 73.62% 99.48% 226.57
P6 Female 9 444 410 7 044 896 74.59% 99.52% 362.23
P7 Male 13 887 662 9 836 275 70.83% 99.51% 505.21
doi:10.1371/journal.pone.0029500.t001
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buffer (Qiagen, Valencia, CA, USA) for each array. A gasket
(Agilent) was applied and placed on a in-house constrcted thermal
elution device for 20 min at 95uC. We repeated this process once,
adding 200 ml of elution buffer (Qiagen). After hybridization of
the sequencing primer, base incorporation was carried out on
Illumina HiSeq2000 Analyzers (following the manufacturer’s
standard cluster generation and sequencing protocols) for 90
cycles of sequencing per read to generate paired-end reads
including 90 bps at each end and 8 bps of the index tag. Image
analysis and base calling were performed using the Illumina
Pipeline.
Data filtering and analysis pipeline
After the entire run was completed, image analyses, error
estimation and base calling were performed using the Illumina
Pipeline (version 1.3.4) to generate primary data. Indexed primers
were used to identify the different reads from different samples in
the primary data, and only reads that were perfectly matched to
the theoretical adapter indexed sequences and reads that matched
the theoretical primer indexed sequences with a maximum of
three mismatches were considered to be acceptable reads. We then
removed a few unqualified sequences from the primary data using
a local dynamic programming algorithm, which included low-
quality reads, defined as reads that contained more than 10
percent Ns in the read length, 50% reads with a quality value of
less than 5 and with an average quality of less than 10 and adapter
sequences including indexed sequence. The remaining sequences
were termed as clean reads for further analysis.
The clean reads with a length of 90 bp were then subjected to
alignment against the reference human genome from the NCBI
database (Build 37) using the BWA (Burrows Wheeler Aligner)
Multi-Vision software package [14]. SNPs and indels were
identified using SOAPsnp software [15] and the GATK Indel
Genotyper (http://www.broadinstitute.org/gsa/wiki/index.php/,
The Genome Analysis Toolkit), respectively. Previously identified
SNPs were determined using the NCBI dbSNP or HapMap
databases. Known disease-causing mutations were identified from
the Human Gene Mutation Database at the Institute of Medical
Genetics in Cardiff (HGMD, http://www.ghmd.cf.ac.uk/) or
from mutations previously reported in the literature.
Sanger sequencing
To verify the DNA sequence variants (substitutions or indels)
detected by NGS, we amplified the target sites and the flanking
sequences of each patient’s DNA template individually with
specific primers designed using Primer6.0. We then sequenced the
PCR products containing potential variants by the Sanger method
to further ascertain the precision of the variants identified by NGS.
Sequencing reactions were performed by mixing 5 ml of previously
purified PCR products (ExoSAP-IT, USB, Cleveland, OH),
0.75 mM of primers and 1 ml of BigDye Terminator v1.1 Cycle
Sequencing kit (Applied Biosystems, Foster City, CA) and were
run in an ABI 3730 DNA Analyzer (Applied Biosystems).
Real-time PCR
To further quantify the DNA copy number change for the
DMD exon in specimens from DMD patients, the relative DNA
copy number level for the DMD exon was measured by
quantitative real-time PCR using the TaKaRa PCR Thermal
Cycler Dice Detection System and SYBR green dye (TaKaRa,
Japan) in three specimens (C2, C3 and P7) according to the
protocol recommended by the manufacturer. A housekeeping
gene, b-actin, was used as an endogenous control. Measurements
were repeated at least three times to ensure the reproducibility of
the results. The DNA copy number level for the DMD exon in
each sample was compared with the level in control blood samples
from normal adult females. The average Ct value of the b-actin
gene was subtracted from the average Ct value for DMD for each
sample: DMD DCt (average DMD Ct – average actin Ct), DMD
DDC (DMD DCt(P) - DMD DCt(N)). The fold change
(2
-MDMDDCt) in DMD copy number relative to b-actin copy
number for each sample examined was calculated. A significant
change was defined as a p value,0.05 [16]. In addition, we used
SIFT software (http://sift.jcvi.org) to predict the pathogenicity of
the single-nucleotide substitution variants.
Results
Sequence enrichment, high-throughput sequencing,
mapping and coverage
To discover DNA variants of disease-causing genes involved in
genetic disorders, we designed a unique high-density capture array
to capture the 3382 exons and adjacent intron sequences of 193
genes causing distinct hereditary diseases (approximately 1.54 Mb,
Table S1) that have a higher incidence in the Chinese population.
Each DNA probe in the array is approximately 60 bp in length,
and the probes can hybridize with all of the targeted exon
sequences plus their flanking sequences (100 bp on each side of the
exon, Table S2). The enriched DNA was sequenced at a single-
base resolution using the Illumina HiSeq2000 Analyzer. To
evaluate this technology, we collected seven samples from seven
patients with six different genetic diseases resulting from six
disease-causing genes as well as 100 samples from normal human
adults as a control. Using Targeted DNA-HiSeq, we obtained a
total of 5,981,308–15,185,260 high-quality reads encompassing
538,317,720–1,366,673,400 high-quality bases per patient
(Table 1, Figure 1). After mapping to the reference human
genome (HG19), 83.74% of the yielded clean reads could be
uniquely matched to target regions, and 99.54% of the targeted
region was covered in at least a 30-fold depth in each sample
(Figure 2). The average coverage depth for exons was 410-fold,
and the highest coverage depth for exons was 1000-fold (Table 1,
Figure 2) across the seven samples. Thus, the coverage should have
been adequate to reliably detect DNA variants within the majority
of the targeted regions.
Estimation of the accuracy of Targeted DNA-HiSeq
To estimate the accuracy of our method, we detected variants of
193 genes in YH DNA using our Targeted DNA-HiSeq
technology and compared the results obtained with the results
from whole-genome sequencing for the same 193 genes in the
same DNA samples deposited in dbSNP (dbYH) [17]. The
variants were considered to be candidate variants according to the
following criteria: (1) the sites were supported by at least 10 reads;
(2) the variant sequence was supported by more than 14% of the
total reads; and (3) the quality value was greater than 20 per base
[18]. Based on the reference genome, we found 1301 SNVs of 193
genes in YH DNA using Targeted DNA-HiSeq, of which 95.70%
(1245/1301) were also identified in dbYH (Figure S1A). To further
ascertain the appropriate ratio of candidate variants in heterozy-
gous genotypes, we compared the distribution ratio of candidate
variants in heterozygous genotypes between common variants
(1245 variants) and specific variants (56 variants) (Figure S1A).
The results showed that the ratio of candidate variants in
heterozygous genotypes was more than 20% in 99.6% (1240/
1245) of common variants (Figure S1B), suggesting that candidate
variants should be supported by more than 20% of the total reads
Analyzing Variants in Genetic Disease Genes
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doi:10.1371/journal.pone.0029500.g001
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identify candidate variants. Based on these new standards, we
found 1281 SNVs of 193 genes in YH DNA (C1) using Targeted
DNA-HiSeq, of which 96.8% (1240/1281) were also identified in
dbYH (Figure 3A and 3B). According to the current results, the
predictive maximum false positive value (FPV) of Targeted DNA-
HiSeq was 3.2% (41/1281). Finally, to further validate the
accuracy of Targeted DNA-HiSeq, 52 candidate variants were
randomly selected and were detected using the MALDI-TOF MS
technique in YH DNA [19]. The results showed that all of the 52
variants identified by our method were confirmed by MALDI-
TOF MS, suggesting that the Targeted DNA-HiSeq approach
that was used in this study has high accuracy and can be applied to
the analysis of clinical samples.
Identification of sequence variants
To identify the variants of 6 disease-causing genes in 7 samples,
the obtained high-quality reads were mapped to the reference
sequence using BWA software, and the variants were then called
using SOAPsnp software and GATK tools according to the above
criteria. We finally identified 6317 variants, including 583 indels
and 5734 substitutes. Among these variants, 84.4% (4841/5734)
were termed as ‘‘known SNVs’’, which were well known SNPs that
had been deposited in the dbSNP database, HGMD, LSMD, and
1000 human genome dataset. To further test the candidate
disease-related mutations, we selected the variants deposited in the
HGMD or LSMD database, identifying 155 known disease-
causing variants. In addition, we found 893 novel variants that had
not been previously reported. Among the novel variants, we
selected 44 variants that were predicted to be truncating
(premature stop/frameshift/splice-site disruption) or to alter an
amino acid, and the presence of two mutations in one gene,
consistent with autosomal recessive inheritance (Figure 1). To find
additional variants, GATK tools were employed to identify small
insertions and small deletions. According to the criteria used to
identify the point mutations described above, 9 candidate indels
located in coding regions and splice sites were chosen for further
analysis (Figure 1).
To exclude interference due to genetic polymorphism, we
sequenced 193 genes in DNA from 100 blood samples from 100
human adults and constructed our own polymorphism database
for these 193 genes. We then considered the variants that did not
overlap with our annotated SNPs (with an allele frequency more
than 5%) for the 193 genes as candidate novel mutations for
further analysis, including 29 known substitutions, 41 novel
substitutions and 9 novel indels. Out of the 79 total candidate
mutations, 7 mutations occurred in 6 disease-causing genes
(Figure 1 and Table 2). In addition, based on results from the
OMIM database, there were an additional 72 candidate mutations
in 49 genes unrelated to the six diseases (Table S3).
Figure 2. Distribution of sequence coverage. (A) The relationship
between sequence coverage and each base pair of the sequenced
exons in the 193 genes in YH DNA. (B) The relationship between median
coverage and each exon number in all of the 10 samples sequenced in
one lane.
doi:10.1371/journal.pone.0029500.g002
Figure 3. Estimation of the accuracy of Targeted DNA-HiSeq
according to the following criteria: (1) sites are supported by at
least 10 reads; (2) a variant sequence is supported by more
than 20% of the total reads for a heterozygous genotype; and
(3) a quality value of greater than 20 per base is obtained. (A)
Venn diagrams of the number of variants in C1 as detected by Targeted
DNA-HiSeq and in dbYH. Based on the reference genome, we found
1281 SNVs of 193 genes in YH DNA using Targeted DNA-HiSeq, of which
96.8% (1240/1281) were also identified in dbYH. (B) The distribution
ratio of candidate variants in heterozygous genotypes between
common variants (1240 variants) and specific variants (41 variants).
doi:10.1371/journal.pone.0029500.g003
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65% of abnormalities in individuals with DMD and 85% of those
in patients with BMD (Becker muscular dystrophy, MIM#
300376) according to GeneReviews. Our results showed a lack
of substitutions or indels in patient P7, who has DMD (Muscular
Dystrophy, Duchenne Type). Therefore, to specifically address
whether a large deletion was present in P7, we analyzed the depth
of all exons of the DMD gene in the proband (P7) and his mother
(C3) by Targeted DNA-HiSeq. Our results showed that the
median read depth for the first exon of the DMD gene was 0 in P7,
whereas the median depth for first exon of the DMD gene in the
proband’s mother (C3) was 334 fold (Figure 4A), and the average
sequencing depth was more than 150 fold in the other 9
individuals sequenced in the same lane with P7 (Figure 4B). To
address whether the low read depth at exon 1 in P7 was due to the
capture or sequencing process, we analyzed the median depth of
exon 1 of the DMD gene in the 100 control specimens, and no
deletion was detected, suggesting that proband (P7) contains a
deletion of exon 1 of the DMD gene that may be associated with
DMD disease. To further confirm the deletion of exon 1 of the
DMD gene in P7, we used quantitative PCR (qPCR) to detect the
DNA copy number of the DMD gene in the proband (P7), his
mother (C3) and a normal female control (C2), with the genomic
b-actin gene being used as a loading control. Our results showed
that the relative amplification level (RA level) was almost zero
(0.032%) in P7, while the RA level was 444 (44.4%) in C2 when
the value of C2 was normalized to 1000 (100%). There were
significant differences between C2 and P7 as well as between C3
and P7 (p,0.001) (Figure 4C), suggesting that there was a
homozygous deletion of exon 1 in the DMD gene in P7 and a
heterozygous deletion in C3 (carrier status).
In addition, among the 7 potential mutations in 6 disease-
causing genes, two novel mutations were identified in two genes
(STS and FBN1), which are involved in X-linked ichthyosis disease
and Marfan syndrome, respectively (Table 2). Our sequencing
results showed that all 10 of the exons of the STS gene (8.2 kb
genomic intervals) exhibited an average coverage of 290 fold with
a single base resolution (Figure 5A). A homozygous substitution
mutation (c.1099G.A; p.G367R) was found in exon 8 of the STS
gene in the DNA of a male patient (P2) that was supported by all
248 reads that spanned this site, and all of the 66 exons in the STS
gene (,25 kb genomic intervals) showed an average coverage of
300 fold with a single base resolution (Figure 5B). All of the 66
exons of the FBN1 gene (24.9-kb genomic intervals) presented an
average coverage of 500 fold, with a single base resolution
(Figure 5C). A substitution mutation (c.175T.C, p.C59R) was
found in exon 3 of the FBN1 gene in the DNA of a female patient
(P3); this substitution is a heterozygous mutation supported by 133
out of the 243 reads that spanned this site (Figure 5D). To predict
the influence of these two variants on protein function, we also
performed an analysis of evolutionary conservation using the
ClustalW tool. This analysis indicated that both of the novel
variants were highly conserved across species. In addition, SIFT
prediction demonstrated that these two mutations were in fact
damaging mutations (Table 2). The current data suggest that these
two variants may play important roles in gene function (Figure 5E
and 5F).
Confirmation of the identified variants by Sanger
sequencing in 7 samples
Using the Targeted DNA-HiSeq method described in this
study, we identified 7 potential mutations in 6 disease-causing
genes, including five previously reported missense or small
insertion or deletion variants in 4 patients (P1, P4, P5 and P6),
two novel missense mutations in P2 and P3 and one exon
deletion mutation in P7 (Table 2). The known homozygous
SPG11 gene mutation (c.2163_2164insT, MIM# 610844) was
detected in patient P1 and was supported by 234 out of the 235
reads [20]. Patient P4, with the rare inherited disorder Wilson’s
disease, presented two known heterozygous ATP7B mutations
(c.2333G.T, p.R778L; c.2810detT, MIM# 606882); 127 of
the 254 reads at this locus carried the prevalent substitution
mutation, and almost half of the reads included the deletion
mutation [21,22]. In the two patients suffering from b-
thalassemia, we identified two different mutations in the b-
subunit of the hemoglobin gene (HBB, MIM# 141900):
126_129delCTTT (269 variants and 421 wild types reads) in
patient P5 and IVS2+654C.T( 1 3 0o f2 5 5r e a d s )i np a t i e n tP 6
[23,24]. To confirm the accuracy of the potential mutations
identified by Targeted DNA-HiSeq, Sanger sequencing based
on PCR was performed to analyze the 7 potential mutations in
t h e6d i s e a s e - c a u s i n gg e n e si nt h es a m es p e c i m e n s .T h er e s u l t s
showed complete consistency between the two methods
(Figure 6A–6G), suggesting that the Targeted DNA-HiSeq
method used in this study provides high accuracy and a very low
false-positive rate.
Table 2. Summary of mutations in seven disease-causing genes from seven genetic diseases.
Sample Disease
Inheritance
manner
a Gene Exon Nucleotide change Amino acid change SIFT
b Comment
P1 HSP-TCC AR SPG11 11 c.2163_2164insT Frameshift defect N.P Known
P2 X-Linked ichthyosis XR STS 8 c.1099G.A p.G367R D Novel
P3 Marfan syndrome AD FBN1 2 c.175T.C p.C59R D Novel
P4 Wilson’s disease AR ATP7B 8 c.2333G.T p.R778L N.P Known
12 c.2810detT Frameshift defect N.P Known
P5 b-Thalassemia AR HBB 2 124_127delTTCT Frameshift defect N.P Known
P6 b-Thalassemia AR HBB 2 IVS2+654C.T Splicing defect N.P. Known
P7 DMD XR DMD 1 Del exon 1 Frameshift deletion N.P. Known
aInheritance manner: AR (autosomal recessive), AD (autosomal dominant) and XR (X-linked recessive).
bSIFT classification: N.P (not predicted) and D (Damaging). Only the two novel variants were predicted with SIFT. SPG11 reference transcript NM_025137; STS reference
transcript NM_000351; FBN1 reference transcript NM_000138; ATP7B reference transcript NM_000053; HBB reference transcript NM_000518; DMD reference transcript
NM_000109.
doi:10.1371/journal.pone.0029500.t002
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Targeted next-generation sequencing has gradually been
applied to simultaneously identify genetic variants in a number
of individuals and provides a reliable measure of target regions and
their potential variants [25]. In this study, we established a next-
generation sequencing technology combined with enrichment of
targeted genes, and this approach was used to detect variants in
3382 exons of 193 genes ultimately resulting in distinct hereditary
diseases that has a higher incidence in the Chinese population
[e.g., a high prevalence of carriers of a-thalassemia (8.53%), b-
thalassemia (2.54%), and both a and b-thalassemia (0.26%)].
Overall, 11.07% of the population in this area was comprised of
heterozygous carriers of a and b-thalassemia [26]. The current
results have demonstrated that this approach can identify DNA
variants with a maximum FPV of 3.2%. The average sequencing
depth for exons is greater than 4006, and the maximum coverage
of the targeted fragments is 99.54%. Seven patients with six
different genetic diseases resulting from six disease-causing genes
were selected to evaluate this technology, and 100 samples from
normal human adults were used as controls. The resulting data
showed that on average, 99.14% of the 3382 exons with more than
30-fold coverage were successfully detected using this technology.
We found a total of six known variants in four disease-causing
genes and two novel mutations in another two disease-causing
genes (STS gene for XLI, FBN1 gene for MFS) as well as one exon
deletion mutation in the DMD gene. All of the candidate
mutations were confirmed by the MOLDI-TOF-MS method,
thereby demonstrating the high accuracy of our method.
However, in addition to the seven mutations identified in these
samples, 72 potential mutations in 43 genes were identified in the
same seven specimens by our method. Each patient carried 10 to
17 (average 13.1) potential mutations that were not in the seven
disease-causing genes according to the OMIM database. Among
these mutations, 71 were heterozygous, and 1 was homozygous.
We found that 27 potential mutations were reported to be related
to 16 different kinds of human diseases, and of these mutations,
51.8% were autosomal dominant (AD), 40.7% were autosomal
recessive (AR), and 7.4% were X-linked recessive (XR) (Dataset
S3). These results suggest that our annotated genetic polymor-
phism database does not present the highest possible level of
representativeness and comprehensiveness, which ultimately
influences our judgment regarding the identification of the
variants. In the future, we will increase the number of specimens
from the control group to obtain a larger polymorphism dataset.
Our results also suggest that one so-called monogenic gene disease
may be associated with multiple disease-causing genes rather than
only one disease-causing gene.
Enrichment of targeted genes in combination with high-
throughput sequencing has been used in the discovery of
theoretical human disease-causing variants, though this approach
has some deficiencies. The genomes of endothermic vertebrates
are characterized by an abundance of CpG islands, the frequency
of which increases in genomic regions with a higher GC content
[27]. Highly GC-rich intervals are difficult to capture and/or
sequence, as has been previously reported [28]. We calculated the
effect of the target sequence GC content on sequencing depth and
found a positive correlation (p,0.001, chi-squared test). More
than 36% of exons with a high GC content (.75%) or low GC
content (,25%) presented a sequencing depth less than 30 fold
(Figure S2A and S2B). When the GC content was greater than
80%, only 14% of the exons could be successfully captured and/or
sequenced to a median depth of greater than 30 fold by our
method. Among the 3382 exons, 29 exons were sequenced, with a
median depth of less than 30-fold across the ten samples (Table
S4). In this set, 19 exons were found in regions with a high or low
GC content, while only 10 exons were found in regions with a
normal GC content. There was a significant difference between
the two groups (p,0.001, z-test). However, this phenomenon may
be related to PCR amplification efficiency. As previously reported,
PCR amplification efficiency is lower in regions with a high GC
content [29]. Because PCR was employed in library construction,
this approach can affect the pre- or post-capture and sequencing
processes in our Targeted DNA-HiSeq system. Based on these
Figure 4. Detection of a deletion mutation of exon 1 in the DMD gene by targeted DNA-HiSeq. (A) Diagram of the median depth,
average depth and sequencing coverage for all 79 exons in the DMD gene. The median/average depth and the sequencing coverage for the first
exon of the DMD gene in patient P7 (proband) was close to 0 and was different from the coverage at exon 1 in the control, C3 (proband’s mother). (B)
The median depth for exon 1 of the DMD gene in all of the 10 samples sequenced in one lane. The median depth for exon 1 was close to 0 in P7, but
not in the other patients. (C) Verification of the deletion mutation in P7 by real-time PCR (mean 6 SEM, ANOVA analysis). The results showed that the
relative amplification (RA) level of exon 1 is nearly 0, and the RA level in C3 is approximately half of the RA level in C2 (p,0.001). Genomic b-actin DNA
was used as a loading control.
doi:10.1371/journal.pone.0029500.g004
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content was closely associated with PCR amplification efficiency in
both probe capture and sequencing processes. To address this
issue, we suggest increasing the denaturation temperature to 98uC
to successfully amplify DNA fragments despite having a GC
content exceeding 78% [30].
Hybridization to a solid-phase array takes almost three days
(65–72 hours) and is a time-consuming process, making array-
based hybridization technology slightly slower for clinical
diagnoses compared with solution-based approaches, which
require approximately 24 hours. Additionally, array-based meth-
ods are hampered with regard to further optimization due to their
technological complexity. If a probe has to be added or changed,
the whole array must be synthesized de novo. A combination of
array- and solution-based platforms for different clinical purposes
needs to be further developed and will provide a favorable
alternative for certain clinical purposes. Multi-sample pooling is
one way to reduce the cost of large-scale genotyping-based disease
association research [31], and the efficiency and cost-effectiveness
of the use of this method in next-generation sequencing has been
evaluated [32]. The 2.1 Mb Nimblegen array used in the method
developed in this study has a target capture size of up to 50 Mb,
and the total amount of data produced for the 193 genes of one
individual is ,1.54 Mb, suggesting that a maximum of 23
individuals can be pooled together on one chip with a capture
efficiency of ,72%. Pooled sample sequencing can be used to
detect both novel sequence variants and rare mutations [33].
In summary, targeted DNA-HiSeq combines next-generation
sequencing with the capture of sequences from a relevant subset of
‘‘high interest’’ genes. This method was tested by capturing
sequences from a DNA library through hybridization to
oligonucleotide probes specific for 193 genetic disorder-related
genes and was found to show high selectivity, to improve mutation
detection enabling the discovery of novel variants, and to provide
Figure 5. Identification of two novel mutations involved in X-linked ichthyosis and Marfan syndrome. (A) Median coverage for all 10
exons of the STS gene. (B) Representative reads aligned to the reference sequence (top) in exon 8 of the STS gene. The arrows indicate the locus with
the substitution mutation (c.1099G.A), as supported by 248 high-quality reads. (C) Median coverage for all 66 exons of the FBN1 gene. (D)
Representative reads aligned to the reference sequence (top) in exon 2 of the FBN1 gene. The arrows indicate the locus with the substitute mutation
(c.175T.C), as supported by 243 high quality reads. (E) Evolutionary conservation analysis of the sequence with a variant (p. G367R) in the STS gene
from 8 species by ClustalW alignment. (F) Evolutionary conservation analysis of the sequence with a variant (p.C59R) in the FBN1 gene from 8 species
by ClustalW alignment.
doi:10.1371/journal.pone.0029500.g005
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analyze the gene variant profiles of monogenic diseases with high
sensitivity, high fidelity, high throughput and high speed.
Supporting Information
Figure S1 Estimation of the accuracy of Targeted DNA-HiSeq
according to the following criteria: (1) sites are supported by at
least 10 reads; (2) variant sequences are supported by more than
14% of the total reads for the heterozygous genotype; and (3) a
quality value of more than 20 per base was obtained. (A) Venn
diagrams of variant numbers in C1 indicated by Targeted DNA-
HiSeq and in dbYH. Based on the reference genome, we found
1301 SNVs of 193 genes in YH DNA using Targeted DNA-
HiSeq, of which 95.70% (1245/1301) were also identified in
dbYH. (B) The distribution of ratio of candidate variants with
heterozygous genotypes between common variants (1245 variants)
and specific variants (56 variants) showed that the ratio of
candidate variants with heterozygous genotypes was greater than
20% in 99.6% (1240/1245) of common variants.
(TIF)
Figure S2 Influence of GC content on sequencing. (A)
Distribution of the median sequence coverage for exons across
10 samples corresponding to the GC content. MSCs, correspond-
ing to the GC content, showed a normal distribution-like behavior
and decreased whenever the GC content of the exon was too high
or low. (B) Histogram of the proportion of exons with ,306MSC
when compared with the number of exons in each GC% range. In
exons with ,25% or .75% GC content, more than 35% of the
exons showed ,306MSC (n=3382, p,0.001, chi-squared test).
MSCs: median sequence coverage across 10 samples.
(TIF)
Table S1 The list of 193 genes causing distinct hereditary
diseases with a higher incidence in the Chinese population.
(XLS)
Table S2 The information of DNA probes designed for the 193
genes including 3382 exons plus their flanking sequences.
(XLS)
Table S3 The list of our own polymorphism database for these
193 genes in 100 blood samples from 100 human adults.
(XLSX)
Table S4 The list of 29 exons with a median depth of less than
30-fold across the ten samples.
(XLS)
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